Drug Profile
Research programme: NF-kappa B inhibitors - Scottish Biomedical
Alternative Names: Research programme: anticancer therapeutics - Scottish Biomedical; SB 41947Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Scottish Biomedical
- Class Small molecules
- Mechanism of Action NF-kappa B inhibitors; Signal transduction pathway inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in Scotland
- 07 Mar 2005 SB 41947 is available for licensing or partnering (http://www.scottish-biomedical.com)
- 07 Mar 2005 Preclinical trials in Cancer in Scotland (unspecified route)